Skip to main content
    B

    Biohaven Ltd. (BHVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $13.82
    +0.00 (+0.00%)

    Market Cap: $2.09B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biohaven Ltd. (BHVN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Biohaven (BHVN) to earn -$1.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $143.33M. Of 17 analysts, 12 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.24, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.

    RatingAnalystsShare
    Strong Buy317.6%
    Buy952.9%
    Hold423.5%
    Sell00.0%
    Strong Sell15.9%
    Consensus
    Buy
    Total analysts
    17

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 27.5%.

    Fiscal year ending Dec 31, 2026
    -$1.39
    EPS consensus, revenue $143.33M
    Fiscal year ending Dec 31, 2027
    -$1.53
    EPS consensus, revenue $103.89M
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.39-$2.85 to -$0.066$143.33MN/A15
    Dec 31, 2027-$1.53-$2.07 to -$0.626$103.89MN/A16

    Quarterly Estimates

    The EPS consensus falls from -$0.20 for the quarter ending Dec 31, 2026 to -$0.46 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.20-$0.83 to $2.0719$43.86MN/A14
    Mar 31, 2027-$0.46-$0.46 to -$0.461$60.05MN/A7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202621
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.41.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.39-$1.30-$1.65-$1.97-$2.41N/A
    Fiscal year ending Dec 31, 2027-$1.53-$1.74-$1.87-$1.94-$1.94N/A
    Quarter ending Mar 31, 2027-$0.46-$0.46-$0.51-$0.51-$0.53N/A

    Frequently Asked Questions About BHVN

    What is the BHVN stock forecast?

    Consensus analyst estimates put Biohaven's EPS at -$1.39 for the fiscal year ending Dec 31, 2026, on revenue of $143.33M. The consensus rating from 17 analysts is Buy.

    How do analysts rate BHVN stock?

    Of 17 analysts covering Biohaven, 3 rate it Strong Buy, 9 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BHVN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.39, with estimates from -$2.85 to -$0.06 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.53, with estimates from -$2.07 to -$0.62 from 6 analysts.

    What revenue do analysts expect from Biohaven next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $143.33M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $103.89M.

    How many analysts cover BHVN?

    17 analysts rate Biohaven stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.